{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:03:00Z","timestamp":1789426980912,"version":"build-2803163510"},"reference-count":45,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>\u00a0Background<\/jats:title><jats:p>Mastocytosis is associated with mast cell (MC) mediator\u2010related symptoms for which limited therapies are available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Our aim was to assess the efficacy and safety of omalizumab in the treatment of MC mediator\u2010related symptoms in adult patients with mastocytosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified one multi\u2010centre retrospective cohort study (39 patients), one retrospective cohort study (13 patients), 4 case series and 10 case reports. No published controlled randomized study was identified. We included 69 patients (13 patients with cutaneous mastocytosis and 56 with systemic mastocytosis). The mean age was 48\u00a0years. Omalizumab maintenance dose was 300\u00a0mg for the majority of patients. The mean duration of treatment was 17\u00a0months. Treatment led to a tolerability of venom immunotherapy and to a complete resolution of severe reactions in all patients with post\u2010honeybee sting anaphylaxis. Complete resolution of idiopathic anaphylaxis episodes was noted in 84% of the patients. Complete resolution of palpitations, gastrointestinal, cutaneous, neuropsychiatric, respiratory and musculoskeletal symptoms was observed at a rate of 43%, 29%, 27%, 11%, 9% and 0%, respectively. Efficacy was maintained for the entire duration of the treatment in all but four responders. Adverse events were reported for 13 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions\u00a0and Clinical Relevance<\/jats:title><jats:p>Omalizumab appears to prevent some life\u2010threatening reactions associated with mastocytosis and may be a good option to treat the associated symptoms. However, the evidence relied upon is observational, uncontrolled and from a small number of patients. A randomized controlled trial is needed to better understand the place of omalizumab in mastocytosis treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cea.13592","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T17:05:12Z","timestamp":1582823112000},"page":"654-661","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Omalizumab in the treatment of adult patients with mastocytosis: A systematic review"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3720-5774","authenticated-orcid":false,"given":"Fatma","family":"Jendoubi","sequence":"first","affiliation":[{"name":"Department of Dermatology Mastocytosis National Reference Center (CEREMAST) Toulouse University Hospital Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gaudenzio","sequence":"additional","affiliation":[{"name":"UDEAR \u2010 H\u00f4pital Purpan UMR 1056 INSERM \u2010 University of Toulouse Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Gallini","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health UMR1027 INSERM\u2010University of Toulouse Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Negretto","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mastocytosis National Reference Center (CEREMAST) Toulouse University Hospital Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mastocytosis National Reference Center (CEREMAST) Toulouse University Hospital Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-6868","authenticated-orcid":false,"given":"Cristina","family":"Bulai Livideanu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mastocytosis National Reference Center (CEREMAST) Toulouse University Hospital Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"issue":"19","key":"e_1_2_10_2_1","first-page":"1885","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides TC","year":"2015","journal-title":"N Engl J Med"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01569.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.12.1578"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-028100"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)70314-2"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2000.00864.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)00403-3"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85538"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215372"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-731893"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.03.039"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13237"},{"issue":"2","key":"e_1_2_10_15_1","first-page":"3","article-title":"The effect of omalizumab in mastocytosis patients. Prospective double\u2010blind, placebo\u2010controlled multicentre study","volume":"143","author":"Distler MMJ","year":"2018","journal-title":"Allergy"},{"key":"e_1_2_10_16_1","first-page":"589","article-title":"long\u2010term follow up (5\u20137 years) of omalizumab treatment in patients with indolent systemic mastocytosis","volume":"68","author":"Filis CVC","year":"2013","journal-title":"Allergy"},{"key":"e_1_2_10_17_1","first-page":"9","article-title":"Treating honey bee venom allergy in mastocytosis\u2010our experience in Adelaide","volume":"44","author":"Fok JSHR","year":"2014","journal-title":"Internal Medicine Journal"},{"key":"e_1_2_10_18_1","first-page":"437","article-title":"Systemic mastocytosis after anaphylactic reactions to hymenoptera venom immunotherapy: Two cases","volume":"71","author":"Demirturk MISR","year":"2016","journal-title":"Allergy"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2013.07.004"},{"key":"e_1_2_10_20_1","first-page":"209","article-title":"Omalizumab in difficult to treat venom allergic patient","volume":"65","author":"Mikos NKL","year":"2010","journal-title":"Allergy"},{"issue":"4","key":"e_1_2_10_21_1","first-page":"1","article-title":"Omalizumab for anaphylaxis during hymenoptera venom immunotherapy","volume":"40","author":"Zubrinich CWE","year":"2010","journal-title":"Intern Med J"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/903541"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.4640"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12848"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.03.032"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02259.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.03.027"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1687"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2010.04.011"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01604.x"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.03.015"},{"issue":"2","key":"e_1_2_10_32_1","first-page":"52","article-title":"Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti\u2010IgE therapy","volume":"45","author":"Paraskevopoulos G","year":"2013","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0395"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.03.009"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.05.011"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri914"},{"key":"e_1_2_10_37_1","unstructured":"European Medicines Agency.Xolair summary of product characteristicshttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000606\/WC500057298.pdf."},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.07.064"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.021"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.70.2.207"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.10.003"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.032"},{"key":"e_1_2_10_43_1","first-page":"30","article-title":"Omalizumab normalizes levels of high affinity immunoglobulin E receptor\u2010positive skin cells in patients with chronic spontaneous urticaria: a randomized, double\u2010blind, placebo\u2010controlled study","volume":"134","author":"Metz MSP","year":"2014","journal-title":"J Invest Dermatol"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200001000-00007"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.7.4167"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1158"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcea.13592","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13592","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cea.13592","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T15:23:38Z","timestamp":1693927418000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cea.13592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1111\/cea.13592"],"URL":"https:\/\/doi.org\/10.1111\/cea.13592","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,25]]},"assertion":[{"value":"2019-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}